Plays a complex role in malignant behavior depending on tumor type and the microenvironment.
In some patients with T-celll non-Hodgkin’s lymphomas and leukemias it is a marker of aggressivity.
It is a prognostic marker for B-cell CLL.
It is a therapeutic target for anti-CD26 monoclonal antibody treatment for lymphoma and renal cell cancer.
CD26 overexpression is a biomarker for the prediction of the response of mesothelioma to chemotherapy.
More than 73% of patients with mesothelioma expressed CD26 on the cell membrane, with a trend to an association between response to chemotherapy and CD26 expression.